The median age at diagnosis of 45 patients with KIT mut/CBF-neg was 46 years old (range: 17–74 years old), including 3 patients with secondary AML, among which one patient was diagnosed as therapy-related AML and two patients progressed from MDS and MPN, respectively. This evidence concerns the gene CEBPZ and myelodysplastic syndrome.